Mazdutide

Mazdutide — GLP-1/Glucagon Dual Agonist by Dragon Pharma

Mazdutide (also known by its research code IBI362 or OXM3) is Dragon Pharma's formulation of the once-weekly GLP-1/Glucagon dual agonist developed by Innovent Biologics in China. It is important to clarify a common misrepresentation: Mazdutide is a GLP-1/Glucagon dual agonist — not a GLP-1/GIP agonist as sometimes incorrectly described. Glucagon receptor agonism adds a mechanistically distinct third dimension to weight loss compared to GLP-1 alone, through hepatic fat mobilisation and thermogenic energy expenditure.

Also searched as: Mazdutide 10mg, IBI362, OXM3, GLP-1 glucagon dual agonist, Mazdutide Dragon Pharma.

The Misclassification — GLP-1/Glucagon vs GLP-1/GIP

This distinction matters mechanistically and should be understood before comparing Mazdutide to other weight loss peptides:

Why Glucagon Agonism Adds a Distinct Weight Loss Pathway

Glucagon is typically known as a counter-regulatory hormone to insulin — it raises blood glucose when glucose is low. However, in the context of a GLP-1/Glucagon dual agonist, Glucagon's metabolic effects produce specific fat-loss benefits that GLP-1 alone cannot achieve:

• Hepatic lipolysis: Glucagon receptor activation in the liver directly stimulates the breakdown of triglycerides stored in liver tissue — making Mazdutide specifically effective for hepatic steatosis (fatty liver), a condition increasingly recognised as connected to metabolic obesity and AAS use at higher doses
• Increased energy expenditure: Glucagon receptor signalling increases thermogenesis — directly raising energy expenditure through brown adipose tissue activation and increased futile cycling in cells. This is a thermogenic effect that GLP-1 receptor agonists alone do not significantly provide
• Why doesn't Glucagon cause dangerous hyperglycaemia in this context? The GLP-1 component provides strong insulin secretagogue activity — the two signals partially balance each other on glucose homeostasis while their lipolytic and appetite effects are additive. At the doses used therapeutically, the net glucose effect is neutral to mildly positive (glucose-lowering)

Clinical Data — Mazdutide Phase II and III

The GLORY-1 Phase III trial (2024) represents Mazdutide's most rigorous efficacy data — ~14% body weight reduction over 48 weeks at 6mg/week. This positions Mazdutide between Semaglutide (~15% at 72 weeks) and Tirzepatide (~20% at 72 weeks) in efficacy, while offering the specific advantage of hepatic fat reduction that GLP-1 alone does not provide as directly.

Mazdutide vs Other Weight Loss Peptides in the Dragon Pharma Range

Effects and Benefits

• Appetite suppression via GLP-1 receptor hypothalamic signalling — reduced hunger and increased satiety
• Hepatic fat mobilisation — direct glucagon receptor-driven lipolysis in liver tissue; relevant for fatty liver conditions
• Increased thermogenic energy expenditure from glucagon receptor signalling
• ~14% body weight reduction over 48 weeks at 6mg/week (GLORY-1 Phase III)
• No suppression of natural testosterone — no PCT required
• Once-weekly dosing from the ~1-week half-life

Dosage and Administration

At 10mg per vial and 6mg/week maintenance dose, one vial provides approximately 1.5 weeks of dosing — users will need approximately 3 vials per month at maintenance. Reconstitute with bacteriostatic water. Unlike peptides requiring fasted dosing, Mazdutide's subcutaneous injection can be taken at any time of the week — consistency of day and time within the week is more important than meal timing.